PSYCH Symposium celebrates successful return to London

PSYCH Symposium, Europe’s leading event in psychedelic medicine, returned to London on July 6th with huge success for the second year running. This 2023 event at the British Museum featured a range of inspiring speakers and panel discussions with the industry’s leading figures, all committed to unlocking the medical and commercial potential of psychedelics.

Founder Stephen Murphy said: “Once more, PSYCH Symposium has been a resounding success. This is Europe’s leading event in psychedelic medicine and we brought together key stakeholders to explore how we expedite the adoption of psychedelic medicine. This year, we highlighted some of the challenges facing the industry and looked at how to improve the investment and funding landscape. We sought to outline clear treatment and regulatory pathways for the industry as it seeks to evolve and ultimately deliver potentially life-changing medicines to patients in need. It was fantastic to hear from so many of the industry’s leading experts and we were delighted to be able to bring everyone together again in such a collaborative environment. I would like to thank everyone for their participation.”

This year’s event highlights included fireside discussions with Professor Robin Carhart-Harris, Professor of Neurology & Psychiatry, Director Psychedelics Division, Neuroscape at UCSF, in ‘Shifting perceptions: Assessing the ways in which psychedelic medicine could help to shape society’; and Christian Angermayer, Founder of Apeiron Investment Group, in ‘Reassessing the psychedelic space: What are the realities of the current market?’.

 PSYCH Symposium also saw panel discussions on new modalities of treatment, including the potential for psychedelics to treat eating disorders and ketamine-assisted therapy to treat addiction. Medicine regulators from Europe and across the globe also explored the pathways to approval; the importance of building robust regulatory frameworks; and how to prepare national healthcare systems for psychedelic-assisted psychotherapy.

More information online